AYVAKIT™ (avapritinib), FDA Approved for Treatment of PDGFRA Exon 18 Mutant GIST, Available at Biologics by McKesson
CARY, N.C., Jan. 17, 2020—Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Blueprint Medicines Corporation as a specialty pharmacy provider for AYVAKIT™ (avapritinib) for the...
TURALIO™ (pexidartinib), FDA Approved Treatment of TGCT, Available at Biologics by McKesson
Exclusive distribution agreement with Daiichi Sankyo, Inc. expands rare disease and complex therapeutic specialty pharmacy needs CARY, N.C. (August 7, 2019) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas,...
NUBEQA® (darolutamide), FDA Approved for Treatment of High-Risk Non-Metastatic Prostate Cancer, Available at Biologics by McKesson
CARY, N.C., August 1, 2019—Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, was selected by Bayer HealthCare as a specialty pharmacy provider for NUBEQA® (darolutamide) for the treatment of non-metastatic...
XPOVIO™ (selinexor) Available for Order at Biologics by McKesson
FDA-approved drug is new treatment option for patients with relapsed or penta-refractory multiple myeloma CARY, N.C., July 8, 2019—Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been...
Biologics by McKesson Expands Specialty Pharmacy Capabilities to Serve Patients with Rare and Complex Conditions
Exclusive distribution agreement for rare disease therapy strengthens the specialty pharmacy’s footprint beyond oncology…
XOSPATA® (gilteritinib) Available at Biologics by McKesson
XOSPATA is FDA Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation…
COPIKTRA (duvelisib) Available for Order at Biologics by McKesson
COPIKTRA is a Dual Inhibitor Approved for Treatment of Adult Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Relapsed or Refractory Follicular Lymphoma CARY, N.C., September 26, 2018—Biologics by McKesson, an...
TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics by McKesson
CARY, N.C. (July 23, 2018) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, has been selected by Agios Pharmaceuticals, Inc. to be in the limited distribution network for TIBSOVO® (ivosidenib), an IDH1...
Combination Therapy BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the Treatment of BRAF-mutant Melanoma, Available for Order at Biologics by McKesson
CARY, N.C. (June 29, 2018) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, has been selected by Array BioPharma, Inc. to be in the limited distribution network for the combination therapy BRAFTOVITM...
TAVALISSE (fostamatinib disodium hexahydrate) Approved by FDA, Available for Order at Biologics by McKesson
CARY, N.C. (May 29, 2018) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced today that it has been selected by Rigel Pharmaceuticals, Inc. to be in the limited distribution network for TAVALISSETM...